Health

OpenAI将英国初创Anima树为医疗样板,患者却称同一个机器人是就医路上的“墙”

OpenAI于10月23日发布的客户案例,恰在Anima进军美国和澳大利亚之际为这家英国初创公司送上一纸厂商背书。案例中75%的等待时间降幅是Anima自己的测算;而就在本月,旺蒂奇的患者把同一个机器人称作挡住就医路的“墙”。

阅读原文

Vincent JiangVincent Jiang · 2 min read
Share
萨姆·奥特曼在一场小组讨论上发言
OpenAI首席执行官萨姆·奥特曼。2026年10月23日,他执掌的公司将英国初创公司Anima——英国国家医疗服务体系(NHS)前台机器人Andi的开发方——列为其医疗行业客户案例。

本月早些时候,英格兰旺蒂奇Newbury Street Practice诊所的患者,把AI前台机器人Andi称作挡在就医路上的“墙”;这个机器人还问过一位65岁的女性,来电是不是咨询怀孕事宜 1。10月23日,OpenAI$500B — OpenAI, private, latest valuation $500B把Andi的开发方、英国初创公司Anima列为医疗行业客户案例,覆盖1000多家诊所、约1400万名患者 2。

既是背书,也是渠道

数字本身就是卖点。Andi构建于GPT-Live之上。接入这款机器人的诊所,电话等待时间从40至50分钟压缩到10分钟左右,降幅至少75%;每月逾80万件病例的处理时长中位数约为3.5小时 2。Anima联合创始人、毕业于剑桥的医生Shun Pang 3表示,在一场比较开源与闭源模型的基准测试中,OpenAI凭借“更优的智能、单位美元智能”胜出 2。这份背书落地之际,Anima正进军美国和澳大利亚市场 2。

每个数字都是Anima自报的

每一项指标都出自Anima自己的测算,再经模型供应商转述;到目前为止,没有任何独立测试证实过这些等待时间数据 4。Anima官网的营销口径比案例研究更激进,宣称电话等待时间缩短超过90% 5。OpenAI的这个医疗样板,无异于客户自己给自己批改作业。

既有证据,也有反证

临床文书吞吐量大约增至三倍:此前每小时归档约15份临床文书的诊所,如今每小时处理30至45份,表现最好的达到45至60份;一些诊所几天内清完了超过10万份积压文书 2。

按Anima自己的统计,使用Anima的诊所文书处理量增至三倍

  • Estimate
0 docs/hr20 docs/hr40 docs/hr60 docs/hr使用Anima前15 docs/hr使用Anima(典型)30–45 docs/hr表现最佳的诊所45–60 docs/hr
Data
ValueRange
使用Anima前15 docs/hr—
使用Anima(典型) (estimate)37.5 docs/hr30–45 docs/hr
表现最佳的诊所 (estimate)52.5 docs/hr45–60 docs/hr
每小时文书量,由Anima在OpenAI 2026年10月23日的客户案例中自行报告;“典型”与“最佳”两根柱取所报区间(30至45份与45至60份)的中值绘制。2

旺蒂奇的这家诊所累计记录超过1.1万次问诊请求,平均每个工作日约180次,预约中超过60%为当日预约;首月正面反馈占79%,第二个月升至84%,诊所方面表示,该服务已通过NHS的合规审核 1。Anima自己的调查显示,愿意再次使用的用户占86%,八九十岁的老人是最满意的用户群体之一 2。仍有一位具名患者,在Andi判定帮不上忙后,排队等了20分钟 1。

资金差距仍未弥合

Anima最近一笔公开披露的融资,是2024年3月的1200万美元A轮融资,由Molten Ventures领投,Hummingbird Ventures、Amino Collective和Y Combinator跟投,完成融资时Anima的服务覆盖150家NHS诊所 3。accuRx此前已融资3660万英镑,Memora Health融资8050万美元,NexHealth融资1.772亿美元 3。这份客户案例没有弥合任何资金差距,却把OpenAI的标志贴在了如今各家对手推销时都要对标的基准上。

对手融资额是Anima 1200万美元A轮的数倍

$0M$50M$100M$150M$200MAnima$12MMemora Health$80.5MNexHealth$177.2M
Data
Value
Anima$12M
Memora Health$80.5M
NexHealth$177.2M
已披露融资额,数据截至TechCrunch 2024年3月20日的报道,本节所有数字均来自该报道;accuRx的3660万英镑因币种不同未纳入比较。3

见分晓的两个指标

目前尚无任何独立验证 4。在独立验证出现之前,不妨盯住两个指标:一是旺蒂奇的月度反馈,看那堵“墙”是否越筑越高;二是Anima下一笔公开披露的融资,它将为这份背书标出价码。

Get Health by email, free

AI in medicine, pharma and biotech. In our daily email, every weekday.

Reader comments

0 comments

    More in Health

    All in this topic →

    Health

    Butterfly Network's record quarter ran on milestone money, and its own Q4 guide says so

    Butterfly Network beat every mark this morning, but the filings show the growth came from chip licensing, not the probe business, and the company's own fourth-quarter guide says that money does not repeat. At 17.6 times sales, the market is paying subscription prices for milestone money.

    Health

    GE HealthCare beat and raised, then filed the exit of the PCS chief to a rival's top job

    The same 8-K filed October 28, 2026, carried a quarter strong enough to raise guidance and the resignation of Jeannette Bankes, who leaves the Patient Care Solutions segment five days after its margin jumped 480 basis points. Investors have to price both at once.

    Health

    Eli Lilly's retatrutide beat Ozempic head-to-head: 20.9% weight loss vs 9.4%, before Novo Nordisk reports

    Lilly's retatrutide beat Ozempic's highest approved dose on blood sugar and cut more than twice the weight in a 1,298-patient Phase 3, published two days before Lilly's Q3 report. Novo's flagship franchise just lost its standard-of-care argument inside the window where payers and investors are repricing it.

    Health

    Bunsen now runs 80% of Schrödinger's own modeling jobs, and November 4 shows if customers pay for it

    Schrödinger's Bunsen agent now runs roughly 80 percent of the computational jobs on the company's own cluster, a reversal for a CEO who called AI drug discovery nonsense in 2024. With full launch due by year-end and Q3 results on Nov. 4, the throughput-licensing model is about to be tested on customers, not just insiders.

    Health

    IQVIA's guidance raise leans on unclosed acquisitions, and $2.1 billion of inactive trials left its backlog

    The beat was clean, but the guidance raise leans on acquisitions still to close and $2.1 billion of inactive trials quietly left the backlog. The 400 AI agents are the more interesting number, and December 1 is where the split gets priced.

    Health

    Globus Medical previews an implant designed in software and placed by its robot, Q3 due November 5

    FDA-cleared but not yet for sale, SCRIPT was previewed at NASS on October 14; its plans import straight into the ExcelsiusGPS robot. With Q3 results due November 5, the earnings test is whether US spine keeps taking share while the robotics business works through its leasing shift.

    Get the newsletter

    The day's AI and market news, in your inbox every weekday.